# Effect of Empagliflozin on Cardiovascular Mortality and Heart Failure Hospitalizations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - processing report

## Source

- Publication: Rauf U, Ansar F, Ali MS, et al. Cureus. 2025;17(6):e85669.
- DOI: `10.7759/cureus.85669`
- PMID: `40642671`
- Source file: `cureus-0017-00000085669.pdf`
- Pages: 11
- SHA-256: `cc5fa0593c4ceccecbd100999984140c8447c5692acbafa168b0bfdd62ac29bd`
- Source type: systematic review and meta-analysis of randomized controlled trials.

## ATOM status

- Publication ID: `92cf45e1-964d-5d77-b724-99f222087a1e`
- Atoms: 54
- By kind: `{"author_conclusion": 5, "conflict_of_interest": 1, "eligibility_criterion": 2, "funding_disclosure": 1, "limitation": 7, "method": 12, "outcome_definition": 2, "population_description": 6, "qualitative_result": 5, "quantitative_result": 12, "study_objective": 1}`
- Authoritative Pydantic structural validation: **PASS**
- Authoritative JSON Schema validation: **PASS**
- Authoritative sufficiency validation: **PASS**
- Structural errors: 0
- JSON Schema errors: 0
- Sufficiency errors: 0
- Sufficiency warnings: 0
- Shared publication identity: **PASS**
- Unique atom IDs: **PASS**

The paper is a secondary synthesis. Trial-specific numerical results are tagged `secondary_reported_result` and remain anchored to the review. The review's pooled meta-analytic results are tagged `review_pooled_result`. No safety outcomes were promoted to adverse-event atoms because the source states that safety outcomes were not included in the review.

## SEA status

All 11 pages were rendered. All five main figures and both main tables were reconciled. The SEA preserves the pooled CV mortality HR 0.86, 95% CI 0.78-0.96, I-squared 73%, and HHF HR 0.70, 95% CI 0.64-0.77, I-squared 0%. Final scoring occurred after figure and table reconciliation. HTML parsing, anchor checks, placeholder scan, and internal-citation-syntax scan passed.

## Source-integrity findings

1. Figure 4 prints the EMPA-TROPISM row as 0.86 [0.78, 0.95], exactly the pooled sensitivity estimate, despite the Results text not reporting a trial-level continuity-corrected HR.
2. Figure 5 prints the EMPA-TROPISM row as 0.70 [0.64, 0.77], exactly the pooled HHF sensitivity estimate. The trial had 84 participants and a zero-event treatment arm; the source value is preserved but not treated as a validated trial effect.
3. The Discussion cites reference 9 for EMPA-TROPISM remodeling and biomarker findings, while the bibliography identifies EMPA-TROPISM as reference 11.
4. The Discussion makes favorable safety statements, while the Conclusions state that safety outcomes were not included in this review. Safety was treated as unsynthesized background.

No discrepancy was silently repaired.

## References

- Numbered bibliography entries extracted: **24/24**
- Output: `rauf-ansar-2025-cureus-85669-reference-task-queue.md`
- Source order preserved.
- Bibliography entries were not atomized.
- No external bibliographic correction was used.

## Governing sources applied

ATOM precedence was followed: supplied `literature.py`, `literature_atoms.py`, `literature_atom.schema.json`, `README(2).md`, and `example_atom.json`. SEA used the supplied `summary-evaluation-appraisal-protocol-v4-compact.md` as governing protocol. The v3 HTML remained historical reference only. `unslop.skill.md` was retrieved from the File Library and applied to prose artifacts. No external verification was performed because `@VERIFY` was not activated.

## Output files

JSON:
- `rauf-ansar-2025-cureus-85669-atoms.json`
- `rauf-ansar-2025-cureus-85669-validation.json`
- `rauf-ansar-2025-cureus-85669-coverage.json`
- `rauf-ansar-2025-cureus-85669-crosswalk.json`
- `rauf-ansar-2025-cureus-85669-sea-qa.json`

HTML:
- `rauf-ansar-2025-cureus-85669-sea.html`

Markdown:
- `rauf-ansar-2025-cureus-85669-reference-task-queue.md`
- `rauf-ansar-2025-cureus-85669-processing-report.md`
